<?xml version="1.0" encoding="UTF-8"?>
<fig fig-type="Figure" xml:lang="en" id="emmm201910938-fig-0002" orientation="portrait" position="float">
 <label>Figure 2</label>
 <caption>
  <title>
   <styled-content style="fixed-case" toggle="no">AAV</styled-content>‐vectored vaccines and 
   <styled-content style="fixed-case" toggle="no">WIV</styled-content> induce broadly reactive antibodies
  </title>
  <p>
   <list list-type="simple" id="emmm201910938-list-0003">
    <list-item>
     <label>A</label>
     <p>Mice were intranasally given 10
      <sup>11</sup> vg of AAV vector in 50 μl volume three times in 3‐week intervals. 20 μg of Cal/7/9 WIV per 50 μl was given i.n. two times. Blood samples were taken at indicated time points (red drops). After influenza challenge, mice were monitored for survival and weight loss for 2 weeks before necropsy.
     </p>
    </list-item>
    <list-item>
     <label>B</label>
     <p>Total IgG ELISA titers expressed as area under the curve (AUC) against homologous Cal/7/9 virus of pre‐immune and pre‐challenge sera of individual animals of the indicated vaccine groups (AAV‐HA, ‐cHA, ‐GFP, WIV 
      <italic>n</italic> = 18, AAV‐NP 
      <italic>n</italic> = 11). Background reactivity of pooled AAV‐GFP pre‐challenge serum is shown as dashed line. ELISAs were performed in technical duplicates.
     </p>
    </list-item>
    <list-item>
     <label>C</label>
     <p>IgA ELISA titers in post‐challenge lung homogenates against Cal/7/9 of individual mice of the indicated vaccine groups (AAV‐HA, ‐cHA, ‐GFP, ‐NP, WIV 
      <italic>n</italic> = 11). of the Cal/7/9 (blue symbols) and PR8 low‐dose (red symbols) challenge groups. ELISAs were performed in technical duplicates.
     </p>
    </list-item>
    <list-item>
     <label>D–G</label>
     <p>Total IgG ELISA titers expressed as log
      <sub>10</sub> of the mean AUC against indicated viruses in pre‐challenge sera in AAV‐HA (D, 
      <italic>n</italic> = 18)‐, AAV‐cHA (E, 
      <italic>n</italic> = 18)‐, AAV‐NP (F, 
      <italic>n</italic> = 11)‐, or WIV (G, 
      <italic>n</italic> = 18)‐immunized animals (gray area). Reactivity of sera of AAV‐GFP‐immunized animals is indicated as white area in the center of each web diagram. ELISAs were performed in technical duplicates.
     </p>
    </list-item>
   </list>Data information: Statistical significance between pre‐immune and pre‐challenge serum was determined using Wilcoxon matched pairs test (
   <sup>###</sup>
   <italic>P</italic> &lt; 0.001). Statistical significance between vaccine groups was determined using Kruskal–Wallis test with Dunn's multiple comparison testing (*
   <italic>P</italic> &lt; 0.05, **
   <italic>P</italic> &lt; 0.01, ***
   <italic>P</italic> &lt; 0.001). Lines indicate mean.
  </p>
 </caption>
 <graphic id="nlm-graphic-7" xlink:href="EMMM-12-e10938-g004" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
